BioSpace News Archive

Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the Barclays 2022 Global Healthcare Conference in Miami, FL on Thursday, March 17, 2022 at 9:00 a.m. ET.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

Conformis, Inc., announced that Gary P. Fischetti has been nominated to stand for election to the Company’s Board of Directors at the Company’s 2022 Annual Meeting of Stockholders, scheduled to be held on May 4, 2022.

ProSomnus Sleep Technologies, the leader in patient-preferred medical devices for the treatment of Obstructive Sleep Apnea, announced the results of four studies evaluating its oral appliance therapy devices as an alternative to continuous positive airway pressure therapy in treating OSA.

Capricor Therapeutics (NASDAQ: CAPR), announced today that The Lancet, a renowned peer-reviewed global medical source for clinical and global health, has published positive results from Capricor’s HOPE-2 Phase 2 clinical trial using lead asset, CAP-1002, to treat patients in advanced stages of Duchenne muscular dystrophy (DMD).

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 13-16 in Nashville, Tenn. and virtually.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership’s participation in two upcoming Investor Conferences this month.

According to Precedence Research, the global surgical equipment market size was valued at USD$ 9.3 billion in 2021 and is predicted to be worth around US$ 15.08 billion by 2028.

The report further provides details about each segments and regions covered in the global Bronchopulmonary Dysplasia Treatment market.

Breast cancer is the most frequently occurring cancer in women, which accounts for about one-third of cancer cases in women and more than 10% of all cancers worldwide.